Previous research has reported that SRD5A1 is highly expressed in prostate cancer (PC) (15, 19, 20), breast cancer (21, 22), non-small cell lung cancer (23), and liver cancer (24). Here, SRD5A1 is linked to non-small cell lung carcinoma.